Coming Soon: Phocus Pharmaceuticals
A specialty CNS company developing new treatment options for acute anxieties.
Striving towards rapid intervention for acute social anxiety.
-
40 million adults
Anxiety disorders are the most common mental illness in the US, affecting 19.1% of adults
-
15 million adults
Social Anxiety Disorder (SAD) affects 7.1% of US adults
-
10+ years
36% of people with SAD report experiencing symptoms for 10+ years before seeking help
*Statistics from Anxiety & Depression Association of America
Social Anxiety Disorder
When faced with new or challenging situations, we all experience some anxiety or feel butterflies in our stomachs.
Social anxiety disorder (SAD) can prevent people from putting their best foot forward in everyday interactions. They may feel fear and dread, their hearts pound, hands tremble and feel nauseous.
Public speaking, job interviews, first dates, networking, professional interactions, medical visits, flying… Millions of people with SAD experience acute fear, significant anxiety and extreme self-consciousness when faced with these, and other, everyday events.
We want to change that.
“We are developing specialty CNS drugs for everyday applications for millions experiencing acute anxiety episodes.
More information will be released on our website upon our launch.”
— PAUL F. TRUEX, CEO & CO-FOUNDER
